Sonntag, 7. März 2021
Navigation öffnen
Anzeige:
Keytruda Pantumor
Keytruda Pantumor
JOURNAL ONKOLOGIE – STUDIE

SENSITIZE 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Rekrutierend

NCT-Nummer:
NCT03278665

Studienbeginn:
September 2017

Letztes Update:
14.09.2020

Wirkstoff:
4SC-202 in combination with Pembrolizumab

Indikation (Clinical Trials):
Melanoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
4SC AG

Collaborator:
-

Studienleiter

Dirk Schadendorf, MD
Principal Investigator
Universitätsklinikum Essen

Kontakt

Studienlocations (3 von 7)

Kinderonkologisches Zentrum Universitätsklinikum Essen
Hufelandstraße 55
45147 Essen
DeutschlandRekrutierend» Google-Maps
Leberkrebszentrum Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
DeutschlandRekrutierend» Google-Maps
Universitätsklinikum Heidelberg
Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Brustzentrum am Klinikum der Universität München
Marchioninistraße 15
80337 München
DeutschlandRekrutierend» Google-Maps
Viszeralonkologisches Zentrum Universitätsklinikum Tübingen
Hoppe-Seyler-Straße 3
72076 Tübingen
DeutschlandRekrutierend» Google-Maps
Onkologisches Zentrum Universitätsklinikum Würzburg
Josef-Schneider-Straße 6
97080 Würzburg
DeutschlandRekrutierend» Google-Maps
Istituto Nazionale Tumori Fondazione "G. Pascale"
Napoli
ItalyRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab. A dose expansion cohort at the Recommended Phase Two Dose (RPTD) will be added.

Adult patients with advanced (unresectable or metastatic) cutaneous melanoma primary refractory or non-responding to anti-PD-1 therapy as most current systemic anti-cancer therapy and for whom no standard therapy is available, will be enrolled. The last administration of anti-PD-1 therapy must have been performed within 6 months prior to screening.

Ein-/Ausschlusskriterien

Main Inclusion Criteria:

- Patients with unresectable stage III or stage IV cutaneous melanoma, as per American Joint Committee on Cancer (AJCC) (Version 8) staging system (must have been histologically confirmed at least once during course of disease). Patients with metastatic tumor of unknown primary site and histology of melanoma are eligible.

- Patients must be primary refractory or non-responding to anti-PD-1 therapy (either as monotherapy or in combination with Ipilimumab)

- Measurable disease by computer tomography (CT) or Magnetic resonance imaging (MRI) per immune-related response evaluation criteria in solid tumors (irRECIST) 1.1 criteria, with longest diameter for non-nodal lesions ≥ 10 mm and ≥ 15 mm in short axis for nodal lesions

- At least one tumor site (either primary site or metastasis) must be accessible for sequential biopsies and patient must consent to the 2 mandatory biopsies. This requirement is not applicable for continuous dosing schedules and may be waived by the sponsor in other individual cases.

Main Exclusion Criteria:

- Patients who achieved a CR or PR, during or after prior anti-PD-1 mono- or anti-CTLA-4/anti-PD-1 combination therapy

- Patients with symptomatic brain metastases/central nervous system (CNS) involvement

- Patients with inadequate organ function

- Therapy with agents known to prolong the QT interval and increase the risk for Torsades de Pointes

Studien-Rationale

Primary outcome:

1. Incidence of Adverse Events [Safety and Tolerability] (Time Frame - Up to 114 weeks):
Safety and tolerability of the combination of 4SC-202 and Pembrolizumab will be assessed from adverse events.



Secondary outcome:

1. Objective Response Rate (ORR) (Time Frame - Up to 102 weeks):
The Objective Response Rate (ORR) will be defined as the percentage of patients who have achieved a confirmed response of at least Immune-related Complete Response (irCR) or Immune-related Partial Response (irPR)

2. Best Overall Response (BOR) (Time Frame - Up to 102 weeks):
The Best Overall Response defined as the best among all confirmed overall responses (irCR is better than irPR is better than irSD)

3. Disease Control Rate (DCR) (Time Frame - Up to 102 weeks):
The Disease Control Rate (DCR) will be defined as the percentage of patients who have achieved a confirmed response of at least irCR or irPR or a response of irSD

4. Duration of Response (DOR) (Time Frame - Up to 102 weeks):
Duration of response (DOR) is defined as the time from the first documentation of response to the date of disease progression. Patients who have no documented disease progression at the end of the study or who are lost to follow-up or who receive additional anti-neoplastic therapy after discontinuing 4SC-202 and Pembrolizumab will be censored at the date of their last extent of disease assessment or on the first date of additional therapy, respectively.

5. Progression Free Survival (PFS) (Time Frame - Up to 102 weeks):
The time from first dosing (C1D1) to date of first observed progression or death from any cause (whichever comes first). Patients who have not progressed while on study and have not died while on study will be censored at the last evaluable assessment date.

6. Time to Progression (TTP) (Time Frame - Up to 102 weeks):
The time from first dosing (C1D1) to first date of first observed progression. Patients who have not progressed while on study, have not died while on study or experienced a non-disease- related death will be censored at the last evaluable assessment date.

7. Overall Survival (OS) (Time Frame - Up to 102 weeks):
The Overall Survival (OS) is defined as the time from first dosing (C1D1) to date of death from any cause. Patients who have not died while on study will be censored at the last evaluable assessment date

Geprüfte Regime

  • 4SC-202 in combination with Pembrolizumab:
    4SC-202 in combination with Pembrolizumab

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Gesundheitliche Beschwerden nicht auf die leichte Schulter nehmen

Gesundheitliche Beschwerden nicht auf die leichte Schulter nehmen
Alexander Raths / Fotolia.com

Arzttermine aus Furcht vor dem Coronavirus auf die lange Bank schieben? Davon rät der Krebsinformationsdienst des Deutschen Krebsforschungszentrums ab. Symptome und Schmerzen sollten ernst genommen und vom Arzt abgeklärt werden. In den meisten Fällen wird es sich nicht um eine schwerwiegende Erkrankung wie Krebs handeln. Wenn aber doch, dann ist es besser, sie möglichst früh zu erkennen und, wenn nötig, sofort zu behandeln – dies erhöht die...

Bewegung hilft bei der Krebstherapie

Bewegung hilft bei der Krebstherapie
© Witthaya / Fotolia.com

Dass Sport und eine Krebserkrankung sich nicht gegenseitig ausschließen, ist inzwischen bekannt. Erwiesenermaßen beugt Sport nicht nur vor, sondern hat auch therapeutische Wirkungen und verbessert die Lebensqualität. Doch wie sieht dies in der Praxis aus und welcher Sport empfiehlt sich in welchem Ausmaß bei welcher Therapie? Aktuell werden immer mehr Studien zu diesem Thema durchgeführt. Das Wohlbefinden des Patienten während und nach der Therapie steht...